BACKGROUND: SRC plays an important role in the pathogenesis of metastatic breast cancer (MBC). In preclinical models, paclitaxel and the oral SRC inhibitor dasatinib showed greater antitumor activity than either agent. To determine the maximum tolerated dose of this combination, we conducted a phase I study. PATIENTS AND METHODS: Patients with MBC; Eastern Cooperative Oncology Group performance status of zero to one; normal hepatic, renal and marrow function were eligible. Paclitaxel 80 mg/m(2) was given 3 weeks of 4. The starting dasatinib dose was 70 mg and was increased, using a standard 3 + 3 dose-escalation scheme. RESULTS: Fifteen patients enrolled (median age 54 years, range 35-74). No dose-limiting toxic effects (DLTs) occurred at dasatinib doses of 70-120 mg. One DLT (grade 3 fatigue) occurred in the dasatinib 150-mg cohort, which was expanded (six patients) with no further DLTs. However, due to cumulative toxic effects (rash, fatigue, diarrhea), the recommended phase II dose is dasatinib 120 mg. Of 13 assessable patients, a partial response was seen in 4 patients (31%), including 2 patients previously treated with taxanes; all received ≥120 mg dasatinib. An additional five patients (29%) had stable disease. CONCLUSION: In combination with weekly paclitaxel, the recommended phase II dose of dasatinib is 120 mg daily and preliminary activity has been seen in patients with MBC.
BACKGROUND:SRC plays an important role in the pathogenesis of metastatic breast cancer (MBC). In preclinical models, paclitaxel and the oral SRC inhibitor dasatinib showed greater antitumor activity than either agent. To determine the maximum tolerated dose of this combination, we conducted a phase I study. PATIENTS AND METHODS: Patients with MBC; Eastern Cooperative Oncology Group performance status of zero to one; normal hepatic, renal and marrow function were eligible. Paclitaxel 80 mg/m(2) was given 3 weeks of 4. The starting dasatinib dose was 70 mg and was increased, using a standard 3 + 3 dose-escalation scheme. RESULTS: Fifteen patients enrolled (median age 54 years, range 35-74). No dose-limiting toxic effects (DLTs) occurred at dasatinib doses of 70-120 mg. One DLT (grade 3 fatigue) occurred in the dasatinib 150-mg cohort, which was expanded (six patients) with no further DLTs. However, due to cumulative toxic effects (rash, fatigue, diarrhea), the recommended phase II dose is dasatinib 120 mg. Of 13 assessable patients, a partial response was seen in 4 patients (31%), including 2 patients previously treated with taxanes; all received ≥120 mg dasatinib. An additional five patients (29%) had stable disease. CONCLUSION: In combination with weekly paclitaxel, the recommended phase II dose of dasatinib is 120 mg daily and preliminary activity has been seen in patients with MBC.
Authors: B S Verbeek; T M Vroom; S S Adriaansen-Slot; A E Ottenhoff-Kalff; J G Geertzema; A Hennipman; G Rijksen Journal: J Pathol Date: 1996-12 Impact factor: 7.996
Authors: Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245
Authors: Shanu Modi; Andrew D Seidman; Maura Dickler; Mark Moasser; Gabriella D'Andrea; Mary Ellen Moynahan; Jennifer Menell; Katherine S Panageas; Lee K Tan; Larry Norton; Clifford A Hudis Journal: Breast Cancer Res Treat Date: 2005-03 Impact factor: 4.872
Authors: Rebecca B Riggins; Keena S Thomas; Huy Q Ta; Jie Wen; Rebecca J Davis; Natasha R Schuh; Stacey S Donelan; Katherine A Owen; Matthew A Gibson; Margaret A Shupnik; Corinne M Silva; Sarah J Parsons; Robert Clarke; Amy H Bouton Journal: Cancer Res Date: 2006-07-15 Impact factor: 12.701
Authors: M Cristofanilli; P Morandi; S Krishnamurthy; J M Reuben; B-N Lee; D Francis; D J Booser; M C Green; B K Arun; L Pusztai; A Lopez; R Islam; V Valero; G N Hortobagyi Journal: Ann Oncol Date: 2008-05-29 Impact factor: 32.976
Authors: Angeles Alvarez Secord; Deanna Teoh; Jingquan Jia; Andrew B Nixon; Lisa Grace; David J Adams; Susan K Murphy Journal: Int J Gynecol Cancer Date: 2014-02 Impact factor: 3.437
Authors: Muralidharan Anbalagan; Alaa Ali; Ryan K Jones; Carolyn G Marsden; Mei Sheng; Latonya Carrier; Yahao Bu; David Hangauer; Brian G Rowan Journal: Mol Cancer Ther Date: 2012-07-10 Impact factor: 6.261